Abbott (NYSE:ABT) said today that it won FDA approval for its Xience Sierra everolimus-eluting coronary stent.
The company’s device features a thin profile, improved flexibility and longer lengths than previous stents. The device and delivery system were designed to help clinicians tackle complex cases, like those involving multiple or totally blocked vessels, according to Abbott.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA approves Abbott’s latest drug-eluting stent appeared first on MassDevice.
from MassDevice https://ift.tt/2IHEfAi
Cap comentari:
Publica un comentari a l'entrada